

Institutional Authorization 45



IA45 Updates and Outreach

CRE Email – June 2024



UHN has set a 45-day target for the Institutional Authorization (IA) process—this major transformational initiative is called “IA45” and is led by the Clinical Research Executive (CRE). To support the development of strategic initiatives in research, UHN has created a new “Strategic Research Projects” team, led by David White, to provide day-to-day project management support to assist in operationalizing new processes and ensure transparency and alignment with UHN’s strategic research goals; this team will be supporting the development and implementation of IA45. Additionally, internal sponsors of IA45 will meet regularly to oversee and coordinate all projects in support of the 45-day target.

The Strategic Research Projects team will be responsible for developing a roadmap, tracking metrics, and ensuring alignment of initiatives across various subgroups and departments. Additionally, the team will be examining the major aspects of the IA process at UHN, looking for opportunities to streamline processes, remove redundancies, and enhance efficiencies. A UHN-wide kick-off and engagement process is planned for early fall.

Transforming UHN’s Institutional Authorization Process



The Clinical Research Executive is actively engaged in collaborating with stakeholders across UHN to streamline and expedite Institutional Authorization (IA) processes. Under the initiative termed IA45, efforts are underway to reduce the average turnaround time for IA from 247 days to 45 days.

The Clinical Research Collaborative Centre is leading a major transformation effort to comprehensively review and improve all aspects of the IA process. This effort implements bold changes to significantly reduce turnaround times—including implementing a 28-day time expectation for CAPCR approval, with any concerns to be flagged by day 14—as well as strategically reviewing the REB process and renewing the CAPCR technology platform.